MA34767B1 - Compositions et procédés pour la modulation de fxr - Google Patents

Compositions et procédés pour la modulation de fxr

Info

Publication number
MA34767B1
MA34767B1 MA36062A MA36062A MA34767B1 MA 34767 B1 MA34767 B1 MA 34767B1 MA 36062 A MA36062 A MA 36062A MA 36062 A MA36062 A MA 36062A MA 34767 B1 MA34767 B1 MA 34767B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
fxr modulation
fxr
present
Prior art date
Application number
MA36062A
Other languages
English (en)
Inventor
David C Tully
Paul Vincent Rucker
Phillip B Alper
Daniel Mutnick
Donatella Chianelli
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA34767B1 publication Critical patent/MA34767B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Abstract

La présente invention concerne des composés de Formule (I), un stéréoisomère, énantiomère, sel pharmaceutiquement acceptable ou son conjugué acide aminé ; les variables étant telles que définies présentement ; et leurs compositions pharmaceutiques qui sont utiles comme modulateurs de l'activité de récepteurs du Farnésoïde X (FXR).
MA36062A 2010-12-20 2013-06-28 Compositions et procédés pour la modulation de fxr MA34767B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061425189P 2010-12-20 2010-12-20
US201161554297P 2011-11-01 2011-11-01
PCT/US2011/062724 WO2012087519A1 (fr) 2010-12-20 2011-11-30 Compositions et procédés pour la modulation de fxr

Publications (1)

Publication Number Publication Date
MA34767B1 true MA34767B1 (fr) 2013-12-03

Family

ID=45349296

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36062A MA34767B1 (fr) 2010-12-20 2013-06-28 Compositions et procédés pour la modulation de fxr

Country Status (38)

Country Link
US (2) US9150568B2 (fr)
EP (1) EP2655370B1 (fr)
JP (1) JP5740483B2 (fr)
KR (1) KR101626046B1 (fr)
CN (1) CN103443099B (fr)
AP (1) AP3414A (fr)
AR (1) AR084425A1 (fr)
AU (1) AU2011345233B2 (fr)
BR (1) BR112013015452B1 (fr)
CA (1) CA2819825C (fr)
CL (1) CL2013001677A1 (fr)
CO (1) CO6801729A2 (fr)
CR (1) CR20130307A (fr)
CU (1) CU24152B1 (fr)
CY (1) CY1119530T1 (fr)
DK (1) DK2655370T3 (fr)
EA (1) EA025569B1 (fr)
ES (1) ES2645728T3 (fr)
GT (1) GT201300159A (fr)
HR (1) HRP20171615T1 (fr)
HU (1) HUE034150T2 (fr)
IL (1) IL226853A (fr)
JO (1) JO3297B1 (fr)
LT (1) LT2655370T (fr)
MA (1) MA34767B1 (fr)
MX (1) MX338845B (fr)
MY (1) MY163216A (fr)
NZ (1) NZ613234A (fr)
PE (1) PE20140207A1 (fr)
PL (1) PL2655370T3 (fr)
PT (1) PT2655370T (fr)
RS (1) RS56335B1 (fr)
SG (1) SG191046A1 (fr)
SI (1) SI2655370T1 (fr)
TW (1) TWI427078B (fr)
UY (1) UY33815A (fr)
WO (1) WO2012087519A1 (fr)
ZA (1) ZA201304044B (fr)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655368A1 (fr) * 2010-12-20 2013-10-30 Irm Llc Compositions et procédés de modulation des récepteurs farnésoïdes x
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
CN103007081B (zh) * 2012-11-27 2013-12-04 鞠法红 一种治疗非酒精性脂肪肝的中药组合物
EP2964230A4 (fr) 2013-03-07 2016-10-26 Califia Bio Inc Inhibiteurs de kinases de lignée mixte et procédés thérapeutiques
MX364834B (es) * 2013-11-05 2019-05-08 Novartis Ag Composiciones y metodos para modular los receptores x farnesoides.
EP3034499A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Nouveaux composés de modulation (FXR NR1H4)
EP3034501A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy contenant des composés de modulation (FXR NR1H4)
AU2015365481B2 (en) * 2014-12-18 2018-08-09 Novartis Ag Azabicyclooctane derivatives as FXR agonists for use in the treatment of liver and gastrointestinal diseases
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
SG10201910670RA (en) 2015-03-31 2020-01-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN106146483A (zh) * 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017133521A1 (fr) * 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Agoniste du récepteur fxr
BR112018016208A2 (pt) * 2016-02-08 2018-12-18 Redx Pharma Plc compostos heterocíclicos, em particular derivados 2-oxo-4,4,5,5,6,6,7,7-octahidrobenzoxazol, e seus usos como compostos antibacterianos
ES2902404T3 (es) * 2016-02-22 2022-03-28 Novartis Ag Métodos para utilizar agonistas de fxr.
EP3842043A1 (fr) * 2016-02-22 2021-06-30 Novartis AG Méthodes d'utilisation d'agonistes de fxr
HUE054819T2 (hu) * 2016-02-22 2021-10-28 Novartis Ag Eljárások FXR agonista alkalmazására
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
WO2017189652A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
CA2968836A1 (fr) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
AR108711A1 (es) * 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN110177783B (zh) * 2016-08-23 2023-06-06 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂
WO2018039384A1 (fr) * 2016-08-23 2018-03-01 Ardelyx, Inc. Composés d'isoxazolyl-carbonyloxy azabicyclo [3.2.1] octane en tant qu'activateurs de fxr
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
KR20210110407A (ko) * 2016-09-14 2021-09-07 노파르티스 아게 Fxr 작용제의 신규 요법
CN108430998B (zh) * 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
BR112019006651A2 (pt) 2016-10-04 2019-07-02 Enanta Pharm Inc análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo
WO2018081285A1 (fr) * 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole contenant de l'urée utilisés comme agonistes de fxr et leurs procédés d'utilisation
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
MX2019009908A (es) 2017-02-21 2019-10-14 Genfit Combinacion de un agonista de ppar con un agonista de fxr.
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
WO2018190643A1 (fr) * 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. Dérivés d'isoxazole en tant qu'agonistes du récepteur nucléaire et leur utilisation
RU2741306C1 (ru) 2017-04-12 2021-01-25 Ил Дон Фармасьютикал Ко., Лтд. Производные изоксазола в качестве агонистов ядерных рецепторов и их применение
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
JP6997870B2 (ja) * 2017-07-06 2022-02-10 シュアンチュー バイオファーマシューティカル カンパニー，リミティド Ｆｘｒ受容体刺激薬
CN109320517B (zh) * 2017-07-31 2021-08-17 轩竹生物科技有限公司 Fxr受体激动剂
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica
MA50242A (fr) * 2017-09-14 2020-07-22 Ardelyx Inc Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques mutagènes et fibrotiques
CN111511731B (zh) * 2017-11-01 2023-05-23 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃化合物
EP3704113B1 (fr) * 2017-11-01 2023-10-11 Bristol-Myers Squibb Company Composés pontés bicycliques en tant que modulateurs du récepteur de farnésoïde x
EA202091101A1 (ru) * 2017-11-01 2020-08-06 Бристол-Маерс Сквибб Компани Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора
SG11202003830SA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Alkene spirocyclic compounds as farnesoid x receptor modulators
EP3704107B1 (fr) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Composés multicycliques en tant que modulateurs du récepteur de farnésoïde x
TW201936189A (zh) 2017-11-30 2019-09-16 瑞士商諾華公司 用於使用fxr激動劑之方法
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN111263759B (zh) 2017-12-22 2023-03-28 四川科伦博泰生物医药股份有限公司 异噁唑衍生物及其制备方法和用途
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (fr) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole en tant qu'agonistes de fxr et leurs procédés d'utilisation
CN110357875B (zh) * 2018-04-10 2022-06-21 浙江海正药业股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途
AU2019276955A1 (en) 2018-05-31 2020-12-03 Novartis Ag Combinations comprising tropifexor and cenicriviroc
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CN112334467B (zh) * 2018-06-26 2023-06-20 轩竹生物科技股份有限公司 Fxr受体激动剂
CN111868056B (zh) * 2018-07-11 2023-02-03 中国医药研究开发中心有限公司 1,2,4-噁二唑类化合物及其制备方法和医药用途
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
ES2907187T3 (es) * 2018-08-08 2022-04-22 Inorbit Therapeutics Ab Compuestos útiles en la modulación del receptor de farnesoide X y métodos de fabricación y uso de los mismos
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
CA3124702A1 (fr) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Composes modulateurs de fxr (nr1h4)
EP3919489A4 (fr) * 2019-01-31 2022-10-12 The National Institutes of Pharmaceutical R&D Co., Ltd Composés cycliques aromatiques ou cycliques hétéroaromatiques, procédé de préparation correspondant et utilisation médicale associée
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
JP2022524820A (ja) 2019-03-13 2022-05-10 ノバルティス アーゲー 医薬組成物
JP7398605B2 (ja) * 2019-04-19 2023-12-15 シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ Ｆｘｒ小分子アゴニストとその調製方法および用途
CN111825667B (zh) * 2019-04-19 2023-07-25 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
CN111825701B (zh) * 2019-04-19 2023-12-08 正大天晴药业集团股份有限公司 含苯并噻唑的三环类fxr调节剂化合物
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CA3140972A1 (fr) 2019-05-20 2020-11-26 Pfizer Inc. Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinees a etre utilisees dans le traitement de la nash/nafld et de maladies associees
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2021014350A1 (fr) 2019-07-23 2021-01-28 Novartis Ag Traitement combiné de maladies hépatiques à l'aide d'agonistes de fxr
KR20220041104A (ko) 2019-07-23 2022-03-31 노파르티스 아게 Fxr 작용제를 포함하는 치료
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
US20220347190A1 (en) 2019-09-19 2022-11-03 Novartis Ag Treatment comprising fxr agonists
JP2022550312A (ja) 2019-09-30 2022-12-01 ノバルティス アーゲー Ｆｘｒアゴニストの使用を含む処置
WO2021104022A1 (fr) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Nouvelle forme cristalline de tropifexor et son procédé de préparation
WO2021104021A1 (fr) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Nouvelle forme cristalline de tropifexor et son procédé de préparation
CA3163979A1 (fr) 2019-12-10 2021-06-17 Pfizer Inc. Formes solides de 2-((4-((s)-2-(5-chloropyridine-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidine-1-yle)methyle)-1-(((s)-oxetan-2-yl)methyle) -1h-benzo[d] imidazole-6-acide carb oxylique, 1,3-dihydroxy-2-(hydroxymethyle)propane-2-sel d'amine
AU2020405182B2 (en) 2019-12-20 2024-03-14 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
WO2021133948A1 (fr) 2019-12-23 2021-07-01 Axcella Health Inc. Compositions et méthodes pour le traitement de maladies et de troubles hépatiques
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists to treat hepatitis d virus infection
IL296694A (en) 2020-03-27 2022-11-01 Pfizer Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts
WO2021233461A1 (fr) * 2020-05-22 2021-11-25 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline d'un composé benzothiazole et son procédé de préparation
US20230226038A1 (en) * 2020-06-09 2023-07-20 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
CN114315830A (zh) * 2020-09-30 2022-04-12 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
AU2022209084A1 (en) 2021-01-14 2023-08-10 Centre Leon Bérard Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN113024552B (zh) * 2021-03-26 2022-08-05 厦门市博瑞来医药科技有限公司 一类新型非甾体fxr激动剂的合成及其应用
CN113292555B (zh) * 2021-04-28 2022-03-18 武汉纽瑞斯医药科技有限公司 一种Tropifexor的制备方法
CA3213217A1 (fr) 2021-04-28 2022-11-03 Raphael Darteil Potentialisation forte d'effets d'agonistes de tlr3 a l'aide d'agonistes de fxr en tant que traitement combine
AU2022336407A1 (en) 2021-08-31 2024-02-22 Pfizer Inc. Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
EP4245365A1 (fr) * 2022-03-16 2023-09-20 Cascade Pharmaceuticals, Inc. Une petite molécule agoniste du récepteur fxr, sa préparation et son utilisation
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
WO2023213801A1 (fr) 2022-05-02 2023-11-09 Precirix N.V. Pré-ciblage
WO2023228023A1 (fr) 2022-05-23 2023-11-30 Pfizer Inc. Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci
WO2024005586A1 (fr) * 2022-06-30 2024-01-04 일동제약(주) Nouvelle forme cristalline d'un dérivé d'isoxazole ou d'un sel de celui-ci
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JPH0672123B2 (ja) 1986-08-21 1994-09-14 セントラル硝子株式会社 トリフルオロメチル基を有するシクロヘキサンカルボン酸の製造方法
AU2003290700A1 (en) 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
KR20080067339A (ko) 2005-11-09 2008-07-18 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그들의 제조법 및 용도
MEP0408A (xx) 2005-12-02 2010-02-10 Pfizer Ltd Derivati hinociklicnog hinazolina kao inhibitori pde7
ES2452031T3 (es) * 2006-02-03 2014-03-31 Eli Lilly & Company Compuestos y procedimientos para modular receptores FX
JP2007230909A (ja) * 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
EP2029558B1 (fr) 2006-05-24 2010-03-10 Eli Lilly And Company Composés et méthodes de modulation de fxr
EP1894924A1 (fr) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
CA2690406A1 (fr) * 2007-07-02 2009-01-08 Glaxosmithkline Llc Agonistes du recepteur de farnesoide x
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
EP2289883A1 (fr) * 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
AU2010313469A1 (en) 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655368A1 (fr) 2010-12-20 2013-10-30 Irm Llc Compositions et procédés de modulation des récepteurs farnésoïdes x
US20140039007A1 (en) 2010-12-20 2014-02-06 David C. Tully Compositions and methods for modulating farnesoid x receptors

Also Published As

Publication number Publication date
BR112013015452A2 (pt) 2016-09-20
PL2655370T3 (pl) 2018-01-31
PT2655370T (pt) 2017-11-14
AP3414A (en) 2015-09-30
CY1119530T1 (el) 2018-03-07
CU24152B1 (es) 2016-02-29
RS56335B1 (sr) 2017-12-29
EP2655370B1 (fr) 2017-08-02
EA201390934A1 (ru) 2013-11-29
TW201302739A (zh) 2013-01-16
AU2011345233A1 (en) 2013-07-18
EP2655370A1 (fr) 2013-10-30
GT201300159A (es) 2014-06-06
US9150568B2 (en) 2015-10-06
MX338845B (es) 2016-05-03
DK2655370T3 (da) 2017-11-06
AU2011345233B2 (en) 2015-11-12
KR20130109210A (ko) 2013-10-07
AR084425A1 (es) 2013-05-15
JP2014500317A (ja) 2014-01-09
CA2819825A1 (fr) 2012-06-28
CN103443099A (zh) 2013-12-11
CU20130082A7 (es) 2013-10-29
BR112013015452B1 (pt) 2021-02-02
KR101626046B1 (ko) 2016-06-01
IL226853A (en) 2015-11-30
JP5740483B2 (ja) 2015-06-24
MX2013007180A (es) 2014-01-23
ZA201304044B (en) 2014-02-26
US20130331349A1 (en) 2013-12-12
AP2013006926A0 (en) 2013-06-30
EA025569B1 (ru) 2017-01-30
CA2819825C (fr) 2019-05-07
CO6801729A2 (es) 2013-11-29
WO2012087519A1 (fr) 2012-06-28
TWI427078B (zh) 2014-02-21
LT2655370T (lt) 2017-10-25
MY163216A (en) 2017-08-30
CL2013001677A1 (es) 2013-12-27
US20150366856A1 (en) 2015-12-24
PE20140207A1 (es) 2014-02-23
JO3297B1 (ar) 2018-09-16
HUE034150T2 (en) 2018-01-29
ES2645728T3 (es) 2017-12-07
UY33815A (es) 2012-07-31
CR20130307A (es) 2013-08-07
HRP20171615T1 (hr) 2017-12-01
CN103443099B (zh) 2016-03-23
NZ613234A (en) 2015-01-30
SG191046A1 (en) 2013-07-31
SI2655370T1 (sl) 2017-12-29

Similar Documents

Publication Publication Date Title
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
MA39088A1 (fr) Compositions et procédés pour moduler des récepteurs farnesoïde x
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA32729B1 (fr) Derives d&#39;acide 1-amino-2-cyclobutylethylboronique
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TN2018000106A1 (en) Farnesoid x receptor modulators
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
MA37519B1 (fr) Composés et compositions pour inhiber l&#39;activité d&#39;abl1, abl2 et bcr-abl1
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu&#39;inhibiteurs de mgat2
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200900048A1 (ru) Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA35716B1 (fr) Formulations pharmaceutiques
EA200870079A1 (ru) Замещенные имидазолы и их применение в качестве пестицидов
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA29839B1 (fr) Derives de carboxamides servant d&#39;antagonistes des recepteurs muscariniques
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d&#39;acétylcholine
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA38250B1 (fr) Nouveau dérivés d&#39;hydantoïne pour leurs utilisations dans le traitement de maladies, comme l&#39;osteoporose et la thrombocytopenie
MA41174B1 (fr) Dérivés d&#39;imidazopyridazine utilisés en tant qu&#39;inhibiteurs de pi3kbeta
TN2012000563A1 (fr) Nouvelle association entre le 4(3-(cis-hexahydrocyclopenta(c)pyrrol-2(1-h)-yl)propoxy)benzamide et un antagoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent.